Immune-checkpoint inhibitors (ICIs), in particular those targeting the Programmed Cell Death-1 or Programmed-Cell Death Ligand-1 (PD-1/PD-L1) axis, have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). Antibodies blocking PD-1/PD-L1 have resulted in improved overall survival either as monotherapy, or in combination with CTLA-4 blockade or chemotherapy (platinum-based, antibody-drug conjugates (ADCs), etc.). However, durable responses are still not observed in most patients, and there is still limited understanding of the mechanisms of response and resistance to anti-PD-1/PD-L1 axis inhibitors. Robust and clinically meaningful biomarkers are also lacking.
Leveraging advances in proteomics, transcriptomics and biology approaches, novel biomarkers can be potentially identified, optimized, and clinically validated to identify mechanisms of response and resistance to immunotherapy. Differential molecular response patterns may also be used to compliment imaging modalities to study immunotherapy response and predict adverse events, to aid clinical decision making and ultimately benefit patients.
This Research Topic aims to explore different biomarker-guided strategies for effective patient selection, treatment de-escalation and immunotherapy-based treatment combinations, including:
1. Resistance mechanisms in the context of immunotherapy in NSCLC.
2. Identification of cellular interactions and molecular alterations within the tumor microenvironment to develop more effective strategies against immunosuppression.
3. Biomarker-guided approaches and combinatorial treatment strategies to improve benefits to immunotherapy in NSCLC.
We are interested in Original Research, Systematic Review, Methods, Review/Mini Review, Clinical Trial, Case Report, Brief Research Report, Study Protocol, and Technology and Code articles focusing on, but not limited to, the following areas:
• Preclinical and clinical treatment approaches that have shown promise in overcoming immunotherapy resistance in NSCLC
• ADCs and immunotherapy combinations in NSCLC in increasing treatment efficacy
• Investigating the role of specific biomarkers for personalized treatment approaches based on predicted response to immunotherapy
• Overcoming challenges in drug delivery to tumor sites and improving drug bioavailability
• Exploiting AI technology for effective patient selection
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords:
Biomarker, immunotherapy, resistance, non-small cell lung cancer, NSCLC
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Immune-checkpoint inhibitors (ICIs), in particular those targeting the Programmed Cell Death-1 or Programmed-Cell Death Ligand-1 (PD-1/PD-L1) axis, have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). Antibodies blocking PD-1/PD-L1 have resulted in improved overall survival either as monotherapy, or in combination with CTLA-4 blockade or chemotherapy (platinum-based, antibody-drug conjugates (ADCs), etc.). However, durable responses are still not observed in most patients, and there is still limited understanding of the mechanisms of response and resistance to anti-PD-1/PD-L1 axis inhibitors. Robust and clinically meaningful biomarkers are also lacking.
Leveraging advances in proteomics, transcriptomics and biology approaches, novel biomarkers can be potentially identified, optimized, and clinically validated to identify mechanisms of response and resistance to immunotherapy. Differential molecular response patterns may also be used to compliment imaging modalities to study immunotherapy response and predict adverse events, to aid clinical decision making and ultimately benefit patients.
This Research Topic aims to explore different biomarker-guided strategies for effective patient selection, treatment de-escalation and immunotherapy-based treatment combinations, including:
1. Resistance mechanisms in the context of immunotherapy in NSCLC.
2. Identification of cellular interactions and molecular alterations within the tumor microenvironment to develop more effective strategies against immunosuppression.
3. Biomarker-guided approaches and combinatorial treatment strategies to improve benefits to immunotherapy in NSCLC.
We are interested in Original Research, Systematic Review, Methods, Review/Mini Review, Clinical Trial, Case Report, Brief Research Report, Study Protocol, and Technology and Code articles focusing on, but not limited to, the following areas:
• Preclinical and clinical treatment approaches that have shown promise in overcoming immunotherapy resistance in NSCLC
• ADCs and immunotherapy combinations in NSCLC in increasing treatment efficacy
• Investigating the role of specific biomarkers for personalized treatment approaches based on predicted response to immunotherapy
• Overcoming challenges in drug delivery to tumor sites and improving drug bioavailability
• Exploiting AI technology for effective patient selection
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords:
Biomarker, immunotherapy, resistance, non-small cell lung cancer, NSCLC
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.